Ghost Tree Capital as of Dec. 31, 2017
Portfolio Holdings for Ghost Tree Capital
Ghost Tree Capital holds 46 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 16.9 | $72M | 850k | 84.87 | |
| Immunomedics | 10.8 | $46M | 2.8M | 16.16 | |
| Allergan | 4.6 | $20M | 121k | 163.58 | |
| Argenx Se (ARGX) | 3.7 | $16M | 250k | 63.14 | |
| Celgene Corporation | 3.7 | $16M | 150k | 104.36 | |
| Esperion Therapeutics (ESPR) | 3.5 | $15M | 230k | 65.84 | |
| Alexion Pharmaceuticals | 3.2 | $14M | 115k | 119.59 | |
| Global Blood Therapeutics In | 3.0 | $13M | 325k | 39.35 | |
| Blueprint Medicines (BPMC) | 2.6 | $11M | 150k | 75.41 | |
| Portola Pharmaceuticals | 2.6 | $11M | 225k | 48.68 | |
| Mirati Therapeutics | 2.6 | $11M | 600k | 18.25 | |
| Sage Therapeutics (SAGE) | 2.5 | $11M | 65k | 164.69 | |
| Mylan Nv | 2.5 | $11M | 250k | 42.31 | |
| Ascendis Pharma A S (ASND) | 2.4 | $10M | 250k | 40.06 | |
| Avexis | 2.2 | $9.4M | 85k | 110.67 | |
| Bristol Myers Squibb (BMY) | 2.2 | $9.2M | 150k | 61.28 | |
| Acceleron Pharma | 2.0 | $8.5M | 200k | 42.44 | |
| Viewray (VRAYQ) | 1.9 | $8.3M | 900k | 9.26 | |
| Dbv Technologies S A (DBVT) | 1.9 | $8.0M | 325k | 24.60 | |
| Zogenix | 1.7 | $7.2M | 180k | 40.05 | |
| Juno Therapeutics | 1.6 | $6.9M | 150k | 45.71 | |
| Clovis Oncology | 1.6 | $6.8M | 100k | 68.00 | |
| La Jolla Pharmaceuticl Com Par | 1.5 | $6.4M | 200k | 32.18 | |
| Array BioPharma | 1.5 | $6.4M | 500k | 12.80 | |
| Obseva Sa | 1.4 | $6.0M | 617k | 9.76 | |
| Aimmune Therapeutics | 1.4 | $6.0M | 158k | 37.82 | |
| Horizon Pharma | 1.4 | $5.8M | 400k | 14.60 | |
| Biohaven Pharmaceutical Holding | 1.2 | $5.0M | 185k | 26.98 | |
| Incyte Corporation (INCY) | 1.1 | $4.7M | 50k | 94.72 | |
| Aquinox Pharmaceuticals | 1.1 | $4.7M | 400k | 11.76 | |
| Dicerna Pharmaceuticals | 1.1 | $4.5M | 500k | 9.03 | |
| Irhythm Technologies (IRTC) | 0.8 | $3.6M | 65k | 56.05 | |
| Crispr Therapeutics (CRSP) | 0.8 | $3.5M | 150k | 23.48 | |
| Inotek Pharmaceuticals | 0.8 | $3.4M | 1.3M | 2.61 | |
| Intellia Therapeutics (NTLA) | 0.8 | $3.4M | 175k | 19.22 | |
| Rigel Pharmaceuticals (RIGL) | 0.8 | $3.2M | 825k | 3.88 | |
| Neos Therapeutics | 0.7 | $3.1M | 300k | 10.20 | |
| Dermira | 0.7 | $2.8M | 100k | 27.81 | |
| Kadmon Hldgs | 0.6 | $2.5M | 700k | 3.62 | |
| Ablynx Nv | 0.5 | $2.2M | 90k | 24.99 | |
| Catalyst Pharmaceutical Partners (CPRX) | 0.5 | $2.2M | 550k | 3.91 | |
| GenMark Diagnostics | 0.5 | $2.1M | 500k | 4.17 | |
| Editas Medicine (EDIT) | 0.5 | $2.0M | 65k | 30.72 | |
| CurrencyShares British Pound Ster. Trst | 0.3 | $1.2M | 9.1k | 131.21 | |
| Nabriva Therapeutics | 0.3 | $1.2M | 200k | 5.98 | |
| Rhythm Pharmaceuticals (RYTM) | 0.2 | $727k | 25k | 29.08 |
